These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 25079039

  • 1. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?
    Pafili K, Papanas N, Maltezos E.
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1277-84. PubMed ID: 25079039
    [Abstract] [Full Text] [Related]

  • 2. Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.
    Geiler J, McDermott MF.
    Curr Opin Mol Ther; 2010 Dec; 12(6):755-69. PubMed ID: 21154167
    [Abstract] [Full Text] [Related]

  • 3. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
    Miller SA, St Onge E.
    Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
    [Abstract] [Full Text] [Related]

  • 4. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.
    Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA, Donath MY.
    Diabetes Care; 2012 Aug; 35(8):1654-62. PubMed ID: 22699287
    [Abstract] [Full Text] [Related]

  • 5. Teplizumab for treatment of type 1 diabetes mellitus.
    Skelley JW, Elmore LK, Kyle JA.
    Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
    [Abstract] [Full Text] [Related]

  • 6. Protection of pancreatic beta-cells: is it feasible?
    Bonora E.
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [Abstract] [Full Text] [Related]

  • 7. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.
    Issafras H, Corbin JA, Goldfine ID, Roell MK.
    J Pharmacol Exp Ther; 2014 Jan; 348(1):202-15. PubMed ID: 24194526
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
    Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A.
    Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus.
    Guglielmi C, Williams SR, Del Toro R, Pozzilli P.
    Expert Opin Biol Ther; 2016 Jun; 16(6):841-6. PubMed ID: 27145230
    [Abstract] [Full Text] [Related]

  • 11. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L, Baker DE, Davis SN, Ratner RE.
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [Abstract] [Full Text] [Related]

  • 12. Prevention versus intervention of type 1 diabetes.
    Brooks-Worrell B, Palmer JP.
    Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E, Nigi L, Patti A, Fondelli C, Dotta F.
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control.
    Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, Delamaire M, Sonnet E, Maugendre D, Maréchaud R, Rohmer V, Saï P, Charbonnel B.
    Diabetes Metab; 2010 Feb; 36(1):64-70. PubMed ID: 20060765
    [Abstract] [Full Text] [Related]

  • 16. Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus.
    Pham DQ, Cohen H, Chu V.
    J Clin Pharmacol; 2007 Jul; 47(7):890-903. PubMed ID: 17585117
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH.
    Am J Ther; 2011 Jul; 18(2):117-52. PubMed ID: 19834322
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H.
    Diabetes Metab Res Rev; 2002 Jul; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.